NetworkNewsBreaks – Pressure BioSciences Inc.’
Post# of 1354
(Total Views: 105)
Posted On: 09/10/2019 4:16:41 PM
NetworkNewsBreaks – Pressure BioSciences Inc.’s (PBIO) PCT Platform Identified as Pivotal for Cancer Biomarker Discovery and Potential Use in Clinical Diagnostics
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the publication of two scientific journal articles led by independent teams of scientists in China and Australia. Per the update, the articles reported excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers, as well as potential use in clinical diagnostics based upon these markers. “It is estimated (Nature volume 448, pages 959–962, 23 August 2007) that well over one billion archival FFPE tissue samples exist in pathology and other laboratories worldwide. We believe there are millions of new FFPE tissue samples processed and stored each year,” Pressure BioSciences President and CEO Richard T. Schumacher said in the news release. “These samples offer the promise of unveiling invaluable information that can lead to the development of new treatments, cures, and preventive measures for cancer and many other diseases. However, up to now, it has been very difficult to extract this information from biomolecules in FFPE samples.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
Pressure BioSciences Inc. (OTCQB: PBIO), a leader in the development and sale of broadly enabling, pressure-based technology and products to the worldwide life sciences and other industries, today announced the publication of two scientific journal articles led by independent teams of scientists in China and Australia. Per the update, the articles reported excellent results with PBI’s Pressure Cycling Technology (“PCT”) platform in processing preserved formalin-fixed paraffin-embedded (“FFPE”) and fresh frozen biopsy tissue samples for discovery and elucidation of cancer biomarkers, as well as potential use in clinical diagnostics based upon these markers. “It is estimated (Nature volume 448, pages 959–962, 23 August 2007) that well over one billion archival FFPE tissue samples exist in pathology and other laboratories worldwide. We believe there are millions of new FFPE tissue samples processed and stored each year,” Pressure BioSciences President and CEO Richard T. Schumacher said in the news release. “These samples offer the promise of unveiling invaluable information that can lead to the development of new treatments, cures, and preventive measures for cancer and many other diseases. However, up to now, it has been very difficult to extract this information from biomolecules in FFPE samples.”
Please see full disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
(0)
(0)Pressure Biosciences (PBIO) Stock Research Links
Scroll down for more posts ▼